A study, published in Molecular Psychiatry, led by Prof. Bernard Lerer from the Department of Psychiatry at the Hadassah—Hebrew University Medical Center shows promising results for using psilocybin, ...
VANCOUVER, British Columbia, April 02, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada licensed psychedelics pharmaceutical manufacturer, ...
VANCOUVER, British Columbia, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading end-to-end drug researcher and formulator licensed by Health Canada, ...
The approval to initiate this Phase 2 clinical trial represents a pivotal moment in the clinical development of Optimi's GMP natural psilocybin extract capsules. Building on its established status as ...
A new study shows that natural mushroom extracts may be more therapeutically effective than synthesized psilocybin, which is widely used in research investigating the medicinal potential of the ...
The DEA has forwarded a petition to change the federal regulatory classification for psilocybin, the psychedelic compound found in "magic mushrooms," to HHS for a medical and scientific review. The ...
Early next year, the state of Colorado will start issuing licenses for psychedelic therapy centers, places where people can pay to take a supervised dose of psychedelic mushrooms and other forms of ...
VANCOUVER, British Columbia, May 11, 2021 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated functional ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results